Factors Affecting the Survival of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Meta-Analysis
- PMID: 31236146
- PMCID: PMC6545752
- DOI: 10.1155/2019/2153170
Factors Affecting the Survival of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Meta-Analysis
Abstract
Background: The aim was to investigate the potential factors related with overall survival of oligometastatic non-small-cell lung cancer (NSCLC) patients.
Methods: A literature search was conducted in databases including PubMed, Embase, and Cochrane library up to March 2017. The hazard radio (HR) as well as the corresponding 95% confidence interval (CI) were calculated, and all the statistics analysis was performed by the R 3.12. Heterogeneity was analyzed using I-squared and Cochran Q tests. Furthermore, sensitivity analysis was performed to evaluate the stability of results.
Results: In total, 6 articles were included in the meta-analysis. Nodal status was significantly correlated with the overall survival rate of NSCLC oligometastatic patients (HR: 1.69, 95% CI: 1.23-2.32, Z=3.20, P=0.001). No significant relationship was found between overall survival rate of NSCLC oligometastatic patients and the indicators including sex, stage, smoker, age, and histology. Notably, sensitivity analysis on data evaluating relationship between patients survival and the stage and histology showed that results were reversed after removing one of the studies.
Conclusions: Nodal status might be associated with the overall survival of oligometastatic NSCLC patients.
Figures



Similar articles
-
Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis.J Thorac Dis. 2018 Jun;10(6):3701-3713. doi: 10.21037/jtd.2018.05.105. J Thorac Dis. 2018. PMID: 30069368 Free PMC article.
-
Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.Lung Cancer. 2019 Apr;130:67-75. doi: 10.1016/j.lungcan.2019.02.006. Epub 2019 Feb 7. Lung Cancer. 2019. PMID: 30885354 Clinical Trial.
-
Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.World J Surg Oncol. 2016 Sep 2;14(1):237. doi: 10.1186/s12957-016-0992-4. World J Surg Oncol. 2016. PMID: 27589869 Free PMC article.
-
Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis.Lung Cancer. 2018 Dec;126:194-200. doi: 10.1016/j.lungcan.2018.11.017. Epub 2018 Nov 13. Lung Cancer. 2018. PMID: 30527187
-
Bone marrow micrometastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis.Interact Cardiovasc Thorac Surg. 2015 Jul;21(1):21-7. doi: 10.1093/icvts/ivv082. Epub 2015 Apr 15. Interact Cardiovasc Thorac Surg. 2015. PMID: 25883247 Review.
Cited by
-
Surgical Management of Oligometastatic Non-Small Cell Lung Cancer.Cancers (Basel). 2025 Jun 18;17(12):2040. doi: 10.3390/cancers17122040. Cancers (Basel). 2025. PMID: 40563689 Free PMC article. Review.
-
Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis.J Thorac Dis. 2022 Apr;14(4):1130-1138. doi: 10.21037/jtd-22-113. J Thorac Dis. 2022. PMID: 35572912 Free PMC article.
References
-
- Komaki R., Tsao A. S., Mehran R. J. 60 Years of Survival Outcomes at the University of Texas MD Anderson Cancer Center. New York, NY, USA: Springer; 2012. Non-small cell lung cancer; pp. 45–62.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical